Bill > HB4610

This bill, titled the Safeguard the Right-To-Try Cutting-Edge Medicine Act, amends West Virginia law to expand access to experimental treatments for individuals with serious illnesses. It removes a previous provision related to individualized treatments and redefines "eligible patient" to include those with a life-threatening or severely debilitating illness, as attested by their physician, who have exhausted all FDA-approved treatment options and received a physician's recommendation for an investigational drug, biological product, or device. The bill also broadens the definition of "investigational drug, biological product or device" to include treatments that are unique and produced specifically for an individual patient based on their genetic profile, such as individualized gene therapy or neoantigen vaccines, in addition to those that have completed phase one of clinical trials but are not yet FDA-approved for general use. Importantly, the bill retains the requirement for written, informed consent from the patient or their legal guardian, detailing potential risks, outcomes, and financial responsibilities.

Health and Social Services, Justice

http://www.wvlegislature.gov/Bill_Status/Bills_history.cfm?input=4610&year=2026&sessiontype=RS&btype=bill